Evusheld

Department of Health and Social Care written question – answered on 10th November 2022.

Alert me about debates like this

Photo of Lord Mendelsohn Lord Mendelsohn Labour

To ask His Majesty's Government, further to the report RAPID C-19 Oversight Group report: review of Evusheld by the RAPID C-19 Oversight Group, published on 6 October, whether they will (1) consult a wider group with more diverse viewpoints and expertise to make a recommendation on the efficacy of Evusheld, and (2) engage other committees with expertise like SAGE and the JCVI on this treatment.

Photo of Lord Mendelsohn Lord Mendelsohn Labour

To ask His Majesty's Government, further to the report RAPID C-19 Oversight Group report: review of Evusheld by the RAPID C-19 Oversight Group, published on 6 October, why (1) SAGE, and (2) the JCVI, were not consulted on the decision on whether to purchase Evusheld.

Photo of Lord Markham Lord Markham The Parliamentary Under-Secretary for Health and Social Care

There are no plans to consult with the Joint Committee on Vaccination and Immunisation or the Scientific Advisory Group on Emergencies as these bodies do not have a remit on decisions on new treatments. RAPID C-19 consists of scientific experts, including clinicians, pharmacists, evidence assessors and researchers, who provide independent clinical advice to the Chief Medical Officer for England. RAPID C-19’s expertise is related to the organisations represented, which include the main healthcare agencies involved in decisions on research, regulation, and introducing new treatments into the National Health Service.

NHS England created a national expert working group (EWG) to support development of a national clinical policy, with a focus on clinical effectiveness and eligibility criteria. The EWG is chaired by a senior NHS representative and the membership includes national experts, frontline clinicians and involves officials from the devolved administrations. The EWG has also considered emerging prophylactic agents and its members have specific expertise in immunology and virology. RAPID C-19 was also advised by the independent COVID-19 Prophylaxis Oversight Group, which is chaired by an expert on infectious diseases and clinical trials.

Does this answer the above question?

Yes0 people think so

No54 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.